Kallikrein-2 inhibitor, cyclic (KLK2b ht2) -1mg

Overview

The Kallikrein-2 inhibitor, cyclic (KLK2b ht2), is a potent inhibitor of the human glandular kallikrein enzyme, kallikrein-2 (KLK2). This enzyme plays a significant role in various physiological processes and is associated with prostate cancer, making it a crucial target for therapeutic intervention. As a head-to-tail cyclic peptide, KLK2b ht2 offers enhanced stability and biological activity, positioning it as a promising candidate for prostate cancer treatment.

Key Features

• Designed to inhibit the activity of KLK2
• High stability and increased biological availability
• Potentially valuable in prostate cancer therapies
• Available in a convenient 1mg package
• Research-grade quality for accurate results

Specifications

FAQ

What is KLK2 and why is it important?

Kallikrein-2 (KLK2) is an enzyme that can be found at elevated levels in the serum of prostate cancer patients. It serves as a biomarker for the disease, making it essential for research and potential therapy development.

How does KLK2b ht2 work?

KLK2b ht2 works by inhibiting the activity of the KLK2 enzyme, which can help prevent the progression of prostate cancer. Its cyclic structure enhances its stability, making it an effective option for targeted therapies.

What are the storage requirements for this peptide?

To maintain its efficacy, KLK2b ht2 should be stored in a cool, dry place away from direct sunlight. Proper storage conditions will help preserve the peptide’s integrity and effectiveness for research or therapeutic use.

If you’re interested in exploring other peptide options for your research or therapeutic needs, check out our extensive selection of peptides. You may also want to explore related products like PKG Substrate and Autocamtide-2.

Related Products

• CREBtide [KRREILSRRPSYR], 5-FAM labeled